Bryostatin 1 in Treating Patients With Ovarian Epithelial Cancer
- Conditions
- Ovarian Cancer
- Registration Number
- NCT00004008
- Lead Sponsor
- University of Glasgow
- Brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients who have ovarian epithelial cancer that has not responded to previous chemotherapy.
- Detailed Description
OBJECTIVES:
* Evaluate the antitumor activity and toxicity of bryostatin 1 in patients with platinum resistant ovarian epithelial cancer.
* Determine the response rate in patients treated with this regimen.
OUTLINE: This is a multicenter study.
Patients receive bryostatin 1 IV over 24 hours. Treatment repeats weekly for 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable or regressive disease may receive additional treatment.
Patients are followed for at least 4 weeks after treatment, then every 3 months.
PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (4)
Royal Infirmary
🇬🇧Glasgow, Scotland, United Kingdom
Christie Hospital N.H.S. Trust
🇬🇧Manchester, England, United Kingdom
Weston Park Hospital
🇬🇧Sheffield, England, United Kingdom
Oxford Radcliffe Hospital
🇬🇧Oxford, England, United Kingdom